Berlin, J. A., B. J. Crowe, E. Whalen, H. A. Xia, C. E. Koro, and J. Kuebler. 2012. Meta-analysis of clinical trial safety data in a drug development program: Answers to frequently asked questions. Clinical Trials 10:20-31.
Downing, N. S., J. A. Aminawung, N. D. Shah, H. M. Krumholz, and J. S. Ross. 2014. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. Journal of the American Medical Association 311(4):368-377.
Eichler, H. G., K. Oye, L. G. Baird, E. Abadie, J. Brown, C. L. Drum, J. Ferguson, S. Garner, P. Honig, M. Hukkelhoven, J. C. W. Lim, R. Lim, M. M. Lumpkin, G. Neil, B. O’Rourke, E. Pezalla, D. Shoda, V. Seyfert-Margolis, E. V. Sigal, J. Sobotka, D. Tan, T. F. Unger, and G. Hirsch. 2012. Adaptive licensing: Taking the next step in the evolution of drug approval. Clinical Pharmacology & Therapeutics 91(3):426-437.
Eichler, H. G., B. Bloechl-Daum, D. Brasseur, A. Breckenridge, H. Leufkens, J. Raine, T. Salmonson, C. K. Schneider, and G. Rasi. 2013. The risks of risk aversion in drug regulation. Nature Reviews Drug Discovery 12(12):907-916.
FDA (U.S. Food and Drug Administration). 2004 (November 23). First monoclonal antibody treatment for multiple sclerosis approved. Press release. Washington, DC: FDA.
FDA. 2009a. Guidance for industry: Format and content of proposed Risk Evaluation and Mitigation Strategies (REMS), REMS assessments, and proposed REMS modifications—Draft guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf (accessed September 11, 2014).
FDA. 2009b. Minutes of the Risk Communication Advisory Committee, FDA. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/riskcommunicationadvisorycommittee/ucm152593.pdf (accessed September 11, 2014).
FDA. 2013. Structured approach to benefit–risk assessment in drug regulatory decision-making: Draft PDUFA V Implementation Plan—February 2013, Fiscal Years 2013-2017. http://patientnetwork.fda.gov/sites/default/files/fda_benefit-risk_draft_plan_final_for_posting.pdf (accessed August 18, 2014).
FDA. 2014. Guidance for industry: Labeling for human prescription drug and biological products approved under the accelerated approval regulatory pathway. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM390058.pdf (accessed September 11, 2014).
Fox, R., A. Salter, J. M. Alster, N. V. Dawson, S. Johnson, M. Kattan, D. Miller, T. Tyry, T. Vollmer, B. Wells, and G. Cutter. 2011. Risk tolerance in MS patients: Survey results from the NARCOMS Registry. American Academy of Neurology Annual Meeting, April 2011, Honolulu, Hawaii.
Frey, P. 2014. Case studies of uncertainty in the assessment of benefits and risks. Presentation at the IOM workshop series on Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products, February 12 and May 12, White Oak, Maryland.
Gagne, J. J., S. V. Wang, J. A. Rassen, and S. Schneeweiss. 2014. A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment. Pharmacoepidemiology and Drug Safety 23:619-627.
Hammad, T. A., S. P. Pinheiro, and G. A. Neyarapally. 2011. Secondary use of randomized controlled trials to evaluate drug safety: A review of methodological considerations. Clinical Trials 8(5):559-570.
Hammad, T. A., G. A. Neyarapally, S. Iyasu, J. A. Staffa, and G. Dal Pan. 2013. The future of population-based postmarket drug risk assessment: A regulator’s perspective. Clinical Pharmacology & Therapeutics 94(3):349-358.
IOM (Institute of Medicine). 2007. The future of drug safety: Promoting and protecting the health of the public. Washington, DC: The National Academies Press.
IOM. 2014. Characterizing uncertainty in the assessment of benefits and risks of pharmaceutical products, Workshop in Brief, Institute of Medicine, Washington, DC.
Krishnamurti, T., S. L. Eggers, and B. Fischhoff. 2008. The impact of over-the-counter availability of “Plan B” on teens’ contraceptive decision making. Social Science & Medicine 67(4):618-627.
Lim, R. 2014. A regulatory approach to uncertainty for the “real world.” Presentation at the IOM workshop series on Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products, February 12 and May 12, White Oak, Maryland.
Mandel, D. R. 2007. Toward a concept of risk for effective military decision making. Defence Research and Development Canada, Toronto Technical Report 2007-124. Toronto, Canada: Defence Research and Development Canada. http://cradpdf.drdc-rddc.gc.ca/PDFS/unc68/p529014.pdf (accessed August 23, 2014).
Parks, M. 2014. Challenges to the regulator in communicating uncertainties in risks of approved pharmaceuticals. Presentation at the IOM workshop series on Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products, February 12 and May 12, White Oak, Maryland.
Savovic, J., H. E. Jones, D. G. Altman, R. J. Harris, P. Juni, J. Pildal, B. Als-Nielsen, E. M. Balk, C. Gluud, L. Lotte Gluud, J. P. A. Ioannidis, K. F. Schulz, R. Beynon, N. J. Welton, L. Wood, D. Moher, J. J. Deeks, and J. A. C. Sterne. 2012. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials. Annals of Internal Medicine 157:429-438.
Schneeweiss, S. 2014. Addressing uncertainties in the evaluation of pharmaceutical benefits and harms during the market access phase. Presentation at the IOM workshop series on Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products, February 12 and May 12, White Oak, Maryland.
Schwartz, L. M, and S. Woloshin. 2011. Communicating uncertainties about prescription drugs to the public: A national randomized trial. JAMA Archives of Internal Medicine 171(16):1463-1468.
Schwartz, L. M., and S. Woloshin. 2013. The drug facts box: Improving the communication of prescription drug information. Proceedings of the National Academy of Sciences of the United States of America 110:14069-14074.
Schwartz, L. M., and S. Woloshin. 2014. Media analysis: Tysabri case study. Presentation at the IOM workshop series on Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products, February 12 and May 12, White Oak, Maryland.
Schwartz, L. M., S. Woloshin, A. Andrews, and T. Stukel. 2012. Influence of medical journal press releases on the quality of associated newspaper coverage: retrospective cohort study. British Medical Journal. http://www.bmj.com/content/bmj/344/bmj.d8164.full.pdf (accessed September 8, 2014).
Tamura, R. N., D. E. Faries, J. S. Andersen, and J. H. Heiligenstein. 1994. A case study of an adaptive clinical trial in the treatment of out-patients with depressive disorder. Journal of the American Statistical Association 89:768-776.
This page intentionally left blank.
